Bod Australia Ltd (ASX: BOD) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


BOD Australia Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.87 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 105.82 million
Earnings per share -0.049
Dividend per share N/A
Year To Date Return -41.67%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Bod Australia Ltd (ASX: BOD)
Latest News

ASX Pot Stocks
Healthcare Shares

Why a COVID-19 trial is exciting BOD (ASX:BOD) investors today?

A clinical trial into the use of medicinal cannabis for long-term COVID-19 is going ahead.

Read more »

three excited doctors with hands in the air
Share Gainers

These 3 ASX Healthcare shares are running hot today

These ASX Healthcare shares have led the way today along with metals and mining.

Read more »

women working with medicinal marijuana, indicating a share price movement in ASX cannabis shares
Share Market News

Why the Bod (ASX:BDA) share price is climbing today

This ASX cannabis stock is on the rise today after a promising sales update

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Cannabis Shares

Up 21%, why the Bod (ASX:BDA) share price is smoking the market today

The Bod (ASX: BDA) share price has surged 21% today following the release of a positive trading update. Here's what…

Read more »

A white cannabis leaf set against a green background with a graph going up, indicating a rising share price for ASX cannabis shares
Share Market News

Bod (ASX:BDA) share price soars on United States market entry

The Bod Australia Ltd (ASX: BDA) share price is soaring after the company announced its first purchased order for the…

Read more »

little green pharma share price represented by cannabis leaf character jumping cheerfully
Share Market News

Why the Bod (ASX:BDA) share price is tracking 5% higher today

The Bod Australia Ltd (ASX: BDA) share price is up more than 5% today following the release of a positive…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
Share Market News

Why the Bod (ASX:BDA) share price is soaring 11%

The Bod share price is soaring 12% today as the company announced strong sales in the second half of CY2020.

Read more »

hand on touch screen lit up by a share price chart moving higher
Share Gainers

Why Atomos, BOD Australia, Galaxy, & Zebit shares are racing higher

Atomos Ltd (ASX:AMS) and Galaxy Resources Limited (ASX:GXY) shares are two of four racing higher on Thursday...

Read more »

BOD ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Bod Australia Ltd

Bod Australia Ltd is engaged in the development and manufacturing of premium CBD and hemp products for consumer markets in Australia and The United Kingdom. It also engages in the development, manufacture, and distribution of therapeutics medicinal cannabis products based on Good Manufacturing Practice. It is organized into three operating segments: medical, over the counter cannabidiol/Hemp ('OTC CBD/Hemp'), and OTC Herbals out of which the OTC CBD/Hemp segment derives the majority revenue.

BOD Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
13 May 2022 $0.14 $-0.01 -6.67% 52,443 $0.14 $0.14 $0.13
12 May 2022 $0.15 $-0.01 -6.25% 231,545 $0.15 $0.16 $0.14
11 May 2022 $0.16 $0.02 13.79% 79,079 $0.15 $0.16 $0.15
10 May 2022 $0.15 $-0.01 -6.67% 223,793 $0.15 $0.15 $0.14
09 May 2022 $0.15 $-0.02 -12.12% 326,427 $0.15 $0.16 $0.14
06 May 2022 $0.17 $0.00 0.00% 81,471 $0.14 $0.17 $0.14
05 May 2022 $0.17 $0.00 0.00% 47,008 $0.17 $0.17 $0.16
04 May 2022 $0.17 $0.02 13.33% 88,013 $0.16 $0.17 $0.15
03 May 2022 $0.15 $-0.02 -12.12% 276,795 $0.16 $0.16 $0.15
02 May 2022 $0.17 $-0.01 -5.88% 149,781 $0.17 $0.17 $0.16
29 Apr 2022 $0.17 $0.00 0.00% 17,882 $0.17 $0.17 $0.15
28 Apr 2022 $0.17 $0.01 6.25% 31,713 $0.16 $0.17 $0.15
27 Apr 2022 $0.16 $0.00 0.00% 15,500 $0.16 $0.16 $0.16
26 Apr 2022 $0.16 $-0.01 -5.88% 255,391 $0.17 $0.17 $0.15
22 Apr 2022 $0.17 $0.00 0.00% 95,892 $0.17 $0.17 $0.16
21 Apr 2022 $0.17 $0.01 6.25% 13,231 $0.16 $0.18 $0.16
20 Apr 2022 $0.16 $-0.01 -6.06% 42,000 $0.18 $0.18 $0.16

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr David Lewis Baker Non-Executive Director Apr 2022
Mr Baker is a commercial advisor and company director with over 40 years of experience in law, investment banking, public company leadership and corporate governance. He has deep industry knowledge across a range of sectors and understanding of financial markets. Mr Baker is a co-founder of Baker Cook Advisory which is a boutique provider of outsourced legal, commercial and governance advice and mediation services for corporations and government agencies.
Ms Joanne (Jo) Patterson Chief Executive OfficerExecutive Director Oct 2016
Ms Patterson has over 20 years of experience in business and corporate strategy with exposure in Australia and international markets. She has developed a number of businesses from start-up as well as driving established organisations. Jo has held multiple CEO and Managing Director roles over her career.
Mr George Livery Non-Executive Director Sep 2018
Mr Livery has over 25 years of experience in senior roles domestically and internationally. Most relevant are his last seven years as director of strategy and corporate development at Swisse Wellness Group, a market leading wellness brand. In addition, George's executive experience is culminated in positions across multiple other industries including the role of chief executive officer at Village Cinemas Australia, chief operating officer of Village International, commercial director at Hoyts Limited, and director of operations and marketing (non-academic services) at the University of Sydney.
Mr Akash Bedi Non-Executive Director Jul 2019
Mr Bedi is Group Senior Director of Strategy and Corporate Affairs at H&H Group. He is based in Hong Kong and is responsible for leading H&H Group's strategy and business development including mergers and acquisitions, and strategic investments for NewH2. He has extensive experience in investing in global start-ups and high growth companies with technologies and businesses that are of strategic importance to H&H Group. Akash has experience in multicultural and global environments. Prior to joining H&H Group, he was a Director of Global Consumer and Retail for HSBC for over a decade.
Mr Mark Masterson Non-Executive DirectorNon-Executive Chairman Nov 2019
Mr Masterson has two decades of experience in the pharmaceutical and healthcare sectors. He began his career with Johnson & Johnson before joining global healthcare giant, Abbott Laboratories (NYSE: ABT) where he held multiple senior positions. Mark also held the role of CEO with Australia's largest private diagnostic imaging network, I-MED. Following the acquisition of I-MED, he was appointed Chairman of Medicines Australia.
Mr Johannes (Hanno) Jacobus Cappon Non-Executive Director Jul 2021
Mr Cappon has experience in biochemistry, nutrition, health and innovation. He has a background in chemistry, life sciences, nutrition and health innovation and developing new consumer and healthcare solutions for commercialization. Mr Cappon is currently Chief Technology Officer at H&H, a position which he has held since January 2021. Mr Cappon's previous senior roles with international companies include VP R&D Nutritionals & Digestive Health at Bayer Consumer Health, Switzerland, as well as VP R&D Nutricia Medical Nutrition at multinational food company Danone Nutricia, Netherlands, amongst others.
Mr Stephen Kelly Company Secretary Sep 2018
Craig Weller Chief Operating Officer
Stephen Kelly Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
New H2 Limited 14,864,865 14.03%
HSBC Custody Nominees (Australia) Limited 10,056,315 9.49%
Health And Beauty Enterprise Pty Limited 5,750,000 5.43%
Noir Ted Pty Ltd 4,852,329 4.58%
Awj Family Pty Ltd 4,445,346 4.20%
Sanlam Private Wealth Pty Ltd 2,500,000 2.36%
Gp Securities Pty Ltd 2,275,416 2.15%
Citicorp Nominees Pty Limited 2,150,592 2.03%
Calama Holdings Pty Ltd 1,332,590 1.26%
Awj Family Pty Ltd (i) 1,216,084 1.15%
Yoix Pty Ltd 1,010,000 0.95%
Baker Cook Advisory Pty Ltd 1,000,000 0.94%
Jimbzal Pty Ltd 1,000,000 0.94%
Twenty Ten Enterprises Pty Ltd 900,050 0.85%
Ms Suzanne Taylor 897,671 0.85%
National Nominees Limited 887,408 0.84%
Jgc Patterson Pty Ltd 800,000 0.76%
Symington Pty Ltd 521,360 0.49%
Mr Kenneth George Parnell & Mrs Lynette Ann Parnell 500,000 0.47%
Bond Street Custodians 441,176 0.42%
Mr John Anthony Redpath 425,901 0.40%